GDNF and Parkinson disease: Pre-clinical and clinical studies to determine the feasibility and safety of CNS- or substantia nigra-targeted GDNF treatment for Parkinson’s disease reported body weight loss and reduced food intake as possible side effects in rats, non-human primates, and humans [2,3,4,5,6,7].